Edition:
India

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

1.14USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$1.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
168,446
52-wk High
$6.64
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Bellicum Pharmaceuticals Reports Q2 2019 Results
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE.QTRLY LOSS PER SHARE $0.58.  Full Article

Bellicum Reports Safety Results For Pancreatic Cancer Drug
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM REPORTS SAFETY RESULTS AND PROMISING ACTIVITY OF ITS CONTROLLED CAR-T CANDIDATE BPX-601 IN PATIENTS WITH ADVANCED PANCREATIC CANCER AT ESMO-IO.BELLICUM PHARMACEUTICALS INC - BPX-601 WAS WELL-TOLERATED WITH NO CRS OR NEUROTOXICITY REPORTED IN INITIAL CELL-DOSE ESCALATION.BELLICUM PHARMACEUTICALS INC - INITIAL EVIDENCE OF BIOLOGIC ACTIVITY AND STABLE DISEASE OBSERVED IN SOME PATIENTS WITH SINGLE RIMIDUCID DOSE.BELLICUM PHARMACEUTICALS INC - RIMIDUCID-ACTIVATED GOCAR-T(®) RESULTED IN SIGNIFICANT EXPANSION AND PERSISTENCE OF T CELLS.BELLICUM PHARMACEUTICALS INC - TO ADD ADDITIONAL TUMOR TYPES IN PART 2 OF STUDY, INCORPORATING STANDARD LYMPHODEPLETION AND REPEAT RIMIDUCID DOSING.BELLICUM PHARMACEUTICALS INC - LOOK FORWARD TO REPORTING UPDATED RESULTS OF BPX-601 STUDY IN 2019.  Full Article

Bellicum Pharmaceuticals Appoints Atabak Mokari As CFO
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS APPOINTS ATABAK MOKARI AS CHIEF FINANCIAL OFFICER.BELLICUM PHARMACEUTICALS INC - APPOINTMENT OF ATABAK MOKARI AS CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 19.BELLICUM PHARMACEUTICALS INC - MOKARI JOINS BELLICUM FROM IRIDEX CORPORATION.  Full Article

Bellicum Pharma Files For Mixed Shelf Of Upto $150 Million
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Bellicum Pharmaceuticals Says On July 13, Co, CFO, Alan Musso Entered Separation Agreement After Which Musso Resigned Effective Aug 31
Tuesday, 17 Jul 2018 

July 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS SAYS ON JULY 13, CO, CFO, ALAN MUSSO ENTERED SEPARATION AGREEMENT AFTER WHICH MUSSO RESIGNED EFFECTIVE AUGUST 31 - SEC FILING.  Full Article

Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501
Thursday, 12 Apr 2018 

April 11 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501.FDA CLINICAL HOLD DID NOT AFFECT BP-004 REGISTRATIONAL TRIAL IN EUROPE, WHICH IS FULLY ENROLLED.LIFT OF CLINICAL HOLD FOLLOWS CONSULTATION WITH FDA & AGREEMENT ON AMENDMENTS TO STUDY PROTOCOLS.BELLICUM WILL BE WORKING WITH U.S. CLINICAL SITES TO RESUME PATIENT RECRUITMENT BASED ON AMENDED PROTOCOLS.  Full Article

Bellicum reports qtrly earnings per share loss‍ $0.71​
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article